Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Bladder Urothelial Carcinoma”

47 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 47 results

Large-scale testing (Phase 3)Ended earlyNCT02982395
What this trial is testing

Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC

Who this might be right for
Non Muscle Invasive Bladder Cancer
Samyang Biopharmaceuticals Corporation 36
Testing effectiveness (Phase 2)Ended earlyNCT01118351
What this trial is testing

Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer

Who this might be right for
Recurrent Bladder CancerTransitional Cell Carcinoma of the Bladder
Case Comprehensive Cancer Center 19
Testing effectiveness (Phase 2)Active Not RecruitingNCT03179943
What this trial is testing

Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma

Who this might be right for
Urothelial Carcinoma
Fox Chase Cancer Center 21
Testing effectiveness (Phase 2)Study completedNCT00003129
What this trial is testing

Chemotherapy in Treating Patients With Early-Stage Bladder Cancer

Who this might be right for
Bladder Cancer
Eastern Cooperative Oncology Group 75
Testing effectiveness (Phase 2)Ended earlyNCT02901548
What this trial is testing

Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder

Who this might be right for
Carcinoma in Situ of BladderBladder Cancer
H. Lee Moffitt Cancer Center and Research Institute 17
Testing effectiveness (Phase 2)Looking for participantsNCT03317158
What this trial is testing

Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder

Who this might be right for
Urothelial CarcinomaBladder Cancer
Noah Hahn, M.D. 55
Testing effectiveness (Phase 2)Study completedNCT01687244
What this trial is testing

Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer

Who this might be right for
Superficial Bladder Cancer
FKD Therapies Oy 40
Testing effectiveness (Phase 2)Study completedNCT02109328
What this trial is testing

Alisertib in Chemotherapy-pretreated Urothelial Cancer

Who this might be right for
Bladder CancerTransitional Cell Carcinoma
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 22
Testing effectiveness (Phase 2)Ended earlyNCT04936230
What this trial is testing

Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer

Who this might be right for
Metastatic Urothelial CarcinomaPlatinum-Resistant Urothelial CarcinomaStage IV Bladder Cancer AJCC v8
National Cancer Institute (NCI) 1
Testing effectiveness (Phase 2)Study completedNCT01620970
What this trial is testing

PF-03446962 in Relapsed or Refractory Urothelial Cancer

Who this might be right for
Transitional Cell Carcinoma of Bladder
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 14
Testing effectiveness (Phase 2)Study completedNCT02009332
What this trial is testing

Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer

Who this might be right for
Non-muscle Invasive Bladder Cancer (NMIBC)
Aadi Bioscience, Inc. 21
Early research (Phase 1)Looking for participantsNCT07218003
What this trial is testing

A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4

Who this might be right for
Non Small Cell Lung CancerCervical CancerHead and Neck Squamous Cell Cancer+7 more
Rondo Therapeutics 149
Large-scale testing (Phase 3)Ended earlyNCT01200992
What this trial is testing

Efficacy and Safety Evaluation of EN3348 (Mycobacterial Cell Wall-DNA Complex [MCC]) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent/Refractory Non-muscle Invasive Bladder Cancer

Who this might be right for
Bladder NeoplasmNeoplasm Recurrence, LocalTransitional Cell, Carcinoma+2 more
Bioniche Life Sciences Inc. 84
Testing effectiveness (Phase 2)Active Not RecruitingNCT04164082
What this trial is testing

Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer

Who this might be right for
Bladder Flat Urothelial Carcinoma In SituNon-Muscle Invasive Bladder Urothelial CarcinomaStage 0a Bladder Cancer AJCC v8+2 more
National Cancer Institute (NCI) 161
Early research (Phase 1)Study completedNCT00016237
What this trial is testing

Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment

Who this might be right for
Bladder CancerKidney CancerLung Cancer
EMD Serono
Testing effectiveness (Phase 2)Looking for participantsNCT06364956
What this trial is testing

Clinical Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial Carcinoma

Who this might be right for
Bladder Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 36
Testing effectiveness (Phase 2)Study completedNCT02769962
What this trial is testing

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer

Who this might be right for
Urothelial CarcinomaUrothelial CancerLung Neoplasms+2 more
National Cancer Institute (NCI) 45
Testing effectiveness (Phase 2)Ended earlyNCT02401542
What this trial is testing

Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma

Who this might be right for
Locally Advanced or Metastatic Urothelial Cell CarcinomaUrinary Bladder DiseaseUrological Diseases
Rainier Therapeutics 71
Testing effectiveness (Phase 2)Study completedNCT00583349
What this trial is testing

Intravesicular Abraxane for Treatment-Refractory Bladder Cancer

Who this might be right for
Bladder Cancer
Columbia University 46
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07322263
What this trial is testing

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

Who this might be right for
Bladder CancerNon-Muscle Invasive Bladder Cancer (NMIBC)Urothelial Carcinoma+8 more
Michael A. O'Donnell 174
Load More Results